These findings provide a rationale to further evaluate AT-101 in combination with standard (chemo-)radiation in Bcl-2-overexpressing tumors, such as head and neck squamous cell carcinoma. This evidence concerns the gene BCL2 and head and neck squamous cell carcinoma.